**Author details**

Coti Phillips1 \*, Edwin Contreras2 and Jessica Oswald1,3,4

1 Department of Anesthesiology, University of California San Diego, La Jolla, United States

2 Department of Emergency Medicine, Kaiser Permanente Southern California, San Diego, United States

3 Center for Pain Management, University of California San Diego, La Jolla, United States

4 Department of Emergency Medicine, University of California San Diego, La Jolla, United States

\*Address all correspondence to: cotiphillips@gmail.com

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**267**

p. 433-442.

p. 1317-0.

*NSAIDs, Opioids, and Beyond*

**References**

120(3): p. 594-606.

Editor. 2018.

[3] and, A.A.C., t.D.S.a.R.M.

*DOI: http://dx.doi.org/10.5772/intechopen.93843*

[9] Matsui, H., et al., *The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine.* 2011. 48(2):

[10] Crofford, L.J., *COX-1 and COX-2 tissue expression: implications and* 

*predictions.* J Rheumatol Suppl, 1997. 49:

[11] *Managing NSAID risks.* Pharmacist's

[12] *Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory* 

[14] Harirforoosh, S., W. Asghar, and F. Jamali, *Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications.* Journal of Pharmacy & Pharmaceutical Sciences,

[15] Hernández-Díaz, S. and L.A.G. Rodríguez, *Association Between Nonsteroidal Anti-inflammatory Drugs and Upper Gastrointestinal Tract Bleeding/Perforation.* Archives of Internal Medicine, 2000. 160(14):

[16] Laine, L., K. Takeuchi, and A. Tarnawski, *Gastric Mucosal Defense and Cytoprotection: Bench to Bedside.* 2008.

[17] Kearney, P.M., et al., *Do selective cyclo-oxygenase-2 inhibitors and* 

*drugs: meta-analyses of individual participant data from randomised trials.* The Lancet, 2013. 382(9894):

[13] García Rodríguez, L. and H. Jick, *Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal antiinflammatory drugs.* 1994. 343(8900):

Letter, 2015. September.

p. 107-111.

p. 15-9.

p. 769-779.

p. 769-772.

2014. 16(5): p. 821.

p. 2093.

135(1): p. 41-60.

[1] Alam, A. and D.N. Juurlink, *The prescription opioid epidemic: an overview for anesthesiologists.* Canadian Journal of Anesthesia/Journal canadien d'anesthésie, 2016. 63(1): p. 61-68.

[2] Laine, L., *Approaches to nonsteroidal anti-inflammatory drug use in the highrisk patient.* Gastroenterology, 2001.

Advisory, and Committee, *FDA Briefing Document: Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee* A. Division of Anesthesia, and Addiction Products (DAAAP)

[4] Paulose-Ram, R., et al., *Frequent monthly use of selected non-prescription* 

*and prescription non-narcotic analgesics among U.S. adults.* Pharmacoepidemiology and Drug Safety, 2005. 14(4): p. 257-266.

[5] Vane, J.R., *The fight against* 

2000. 51(4 Pt 1): p. 573-86.

*rheumatism: from willow bark to COX-1 sparing drugs.* J Physiol Pharmacol,

[6] Bjordal, J.M., *Non-steroidal antiinflammatory drugs, including cyclooxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials.* 2004. 329(7478):

[7] Romsing, J., et al., *Reduction of opioid-related adverse events using opioidsparing analgesia with COX-2 inhibitors lacks documentation: A systematic review.* Acta Anaesthesiologica Scandinavica,

[8] Fitzgerald, G.A. and C. Patrono, *The Coxibs, Selective Inhibitors of Cyclooxygenase-2.* New England Journal of Medicine, 2001. 345(6):

2005. 49(2): p. 133-142.

*NSAIDs, Opioids, and Beyond DOI: http://dx.doi.org/10.5772/intechopen.93843*
